{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'IND', 'Investigational New Drug', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive Response Technology', 'ITC', 'Inter treatment cycle', 'IV', 'Intravenous', 'IVIg', 'Intravenous immunoglobulin', 'LRP4', 'Lipoprotein receptor-related protein-4', 'LS', 'Least square means', 'MG', 'Myasthenia gravis', 'MG-ADL', 'Myasthenia Gravis Activities of Daily Living', 'MGC', 'Myasthenia Gravis Composite', 'MGFA', 'Myasthenia Gravis Foundation of America', 'MG-QoL15r', '15-item Quality of life scale for Myasthenia Gravis [revised', 'version]', 'mITT', 'modified Intention-To-Treat', 'MMRM', 'Mixed Models for Repeated Measurements', 'MuSK', 'Muscle-specific kinase', 'NCI', 'National Cancer Institute', 'NSID', 'Non-steroidal immunosuppressive drug', 'PD', 'Pharmacodynamics', 'PHQ-9', 'Patient Health Questionnaire item 9', 'PLEX', 'Plasma Exchange', 'PK', 'Pharmacokinetics', 'PP', 'Per protocol', 'QMG', 'Quantitative Myasthenia Gravis', 'SAE', 'Serious adverse event', 'SEB', 'Study entry baseline', 'SoA', 'Schedule of assessments', 'SoC', 'Standard of care', 'SOP', 'Standard operating procedures', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'TCB', 'Treatment cycle baseline', 'TC1B', 'First Treatment Cycle Baseline', 'TCnB', 'Subsequent Treatment Cycle Baseline', 'TEAE', 'Treatment-emergent adverse event', 'UN', 'Unstructured covariance structure', 'UNS', 'Unscheduled visit', 'US', 'United States', 'WBC', 'White blood cell', 'WHO(-DD)', 'World Health Organization (drug dictionary)', 'argenx BVBA', 'Confidential', 'Page 39 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'DEFINITION OF TERMS', 'Blinding:', 'A procedure in which one or more parties to the trial are kept', 'unaware of the treatment assignment in order to reduce the', 'risk of biased trial outcomes. The level of blinding is', 'maintained throughout the conduct of the trial, and only', 'when the data are cleaned to an acceptable level of quality', 'will appropriate personnel be unblinded or when required in', 'case of a (serious) adverse event ([S]AE). In a double-blind', 'trial, the subject, the Investigator and Sponsor staff who are', 'involved in the treatment or clinical evaluation of the', 'subjects and the review or analysis of data are all unaware of', 'the treatment assignment.', 'Childbearing potential:', 'Women of childbearing potential are defined as all female', 'participants unless they are postmenopausal (defined by', 'continuous amenorrhea) for at least 2 years with a follicle-', 'stimulating hormone (FSH) > 40 IU/L or are surgically', 'sterile (i.e., who had a hysterectomy, bilateral oophorectomy,', 'or have current documented tubal ligation or any other', 'permanent female sterilization procedure). Determination of', 'FSH levels can be used to confirm postmenopausal status in', 'amenorrheic patients not on hormonal replacement therapy if', 'the test result is within the postmenopausal range per the', 'central laboratory.', 'Council for International', 'The Council for International Organizations of Medical', 'Organizations of Medical', 'Sciences (CIOMS) is an international, non-governmental,', 'Sciences (CIOMS):', 'non-profit organization established jointly by the World', 'Health Organization (WHO) and UNESCO in 1949. They', 'provide a set of ethical principles regarding human', 'experimentations, including International Reporting of', 'Adverse Drug Reactions and International Reporting of', 'Periodic Drug-Safety Update Summaries.', 'The CIOMS form provides a standardized format for the', 'reporting of suspected adverse reactions to any particular', 'medical product and is the acceptable and widely used', 'format for reporting suspect adverse drug reaction', '(ADR)/suspected unexpected serious adverse reaction', '(SUSAR) in clinical trials.', 'argenx BVBA', 'Confidential', 'Page 40 of 110']\n\n###\n\n", "completion": "END"}